Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Zheng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6276-1831; OpenAlex author ID A5115695245. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper

Papers 9

  1. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  2. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. Co-author DOI 10.1016/j.isci.2021.103400↗
  3. Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiotherapy With Non-V600 BRAF Mutation Locally A… Co-author DOI 10.21203/rs.3.rs-809969/v1↗
  4. Hyperglycemia Promotes Pancreatic Cancer Initiation and Progression by Activating the Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.2174/1871520621666210201095613↗
  5. NGF from pancreatic stellate cells induces pancreatic cancer proliferation and invasion by PI3K/AKT/GSK signal pathway. Co-author DOI 10.1111/jcmm.15265↗
  6. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway. Co-author DOI 10.1111/jcmm.14167↗
  7. Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients. Last author DOI 10.18632/aging.101785↗
  8. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  9. Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. Co-author DOI 10.3892/ijo.2018.4295↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liang Han · 3 shared papers, 2019–2021 · strength 0.40
  2. Qingyong Ma · 4 shared papers, 2018–2022 · strength 0.39
  3. Chang Liu · 2 shared papers, 2019–2021 · strength 0.27
  4. Hui-Ming Chen · 2 shared papers, 2019–2021 · strength 0.27
  5. Jie Jiang · 2 shared papers, 2019–2020 · strength 0.27
  6. Tao Qin · 2 shared papers, 2019–2020 · strength 0.27
  7. Wei Li · 2 shared papers, 2018–2021 · strength 0.22
  8. Zheng Wu · 2 shared papers, 2018–2021 · strength 0.22
  9. Weikun Qian · 2 shared papers, 2018–2021 · strength 0.20
  10. Wanxing Duan · 2 shared papers, 2018–2021 · strength 0.20
  11. Chen Chang · 1 shared paper, 2021 · strength 0.13
  12. Xin Chen · 1 shared paper, 2021 · strength 0.13
  13. Ke Cheng · 1 shared paper, 2021 · strength 0.13
  14. Dan Cao · 1 shared paper, 2021 · strength 0.13
  15. Ying Xiao · 1 shared paper, 2019 · strength 0.12
  16. Xing Zhang · 1 shared paper, 2019 · strength 0.10
  17. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  18. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  19. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  20. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  21. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  22. Gang Ren · 1 shared paper, 2022 · strength 0.09
  23. Jie Chen · 1 shared paper, 2022 · strength 0.09
  24. Dan Cao · 1 shared paper, 2022 · strength 0.09
  25. Jian Wang · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.